APG-2449 + pegylated liposomal doxorubicin

APG-2449 + pegylated liposomal doxorubicin is an experimental combination therapy currently under investigation for cancer treatment. APG-2449 is a small molecule, orally active, third-generation, multitargeted tyrosine kinase inhibitor that inhibits focal adhesion kinase (FAK), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), as well as other kinases such as IGF1R, LRRK2, and LTK[1][3][4]. Pegylated liposomal doxorubicin is a liposome-encapsulated formulation of doxorubicin, an anthracycline chemotherapy agent that inhibits topoisomerase II, thereby blocking DNA replication and cancer cell proliferation. The pegylated liposomal formulation is engineered to remain in the bloodstream longer, allowing more of the drug to reach tumors and reducing exposure to healthy tissue[2][5]. The combination is mainly being studied in advanced solid tumors, including ovarian cancer and non-small cell lung cancer (NSCLC), aiming to overcome resistance mechanisms and improve anticancer efficacy[3][4][6].

Other names

doxorubicin hydrochloride liposomepegylated doxorubicinpegylated liposomal doxorubicin